AGTI vs. VIR, GMTX, BKD, KNSA, GYRE, OMCL, ANIP, ALHC, AKRO, and FDMT
Should you be buying Agiliti stock or one of its competitors? The main competitors of Agiliti include Vir Biotechnology (VIR), Gemini Therapeutics (GMTX), Brookdale Senior Living (BKD), Kiniksa Pharmaceuticals (KNSA), Gyre Therapeutics (GYRE), Omnicell (OMCL), ANI Pharmaceuticals (ANIP), Alignment Healthcare (ALHC), Akero Therapeutics (AKRO), and 4D Molecular Therapeutics (FDMT). These companies are all part of the "medical" sector.
Agiliti (NYSE:AGTI) and Vir Biotechnology (NASDAQ:VIR) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, community ranking, valuation, risk, media sentiment and analyst recommendations.
99.1% of Agiliti shares are owned by institutional investors. Comparatively, 65.3% of Vir Biotechnology shares are owned by institutional investors. 4.2% of Agiliti shares are owned by insiders. Comparatively, 15.6% of Vir Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Agiliti has a net margin of -1.65% compared to Vir Biotechnology's net margin of -677.69%. Agiliti's return on equity of 6.47% beat Vir Biotechnology's return on equity.
Agiliti has higher revenue and earnings than Vir Biotechnology. Agiliti is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.
In the previous week, Vir Biotechnology had 1 more articles in the media than Agiliti. MarketBeat recorded 1 mentions for Vir Biotechnology and 0 mentions for Agiliti. Vir Biotechnology's average media sentiment score of 0.60 beat Agiliti's score of 0.00 indicating that Vir Biotechnology is being referred to more favorably in the news media.
Agiliti currently has a consensus target price of $14.17, indicating a potential upside of 40.96%. Vir Biotechnology has a consensus target price of $33.57, indicating a potential upside of 245.03%. Given Vir Biotechnology's stronger consensus rating and higher probable upside, analysts plainly believe Vir Biotechnology is more favorable than Agiliti.
Agiliti received 3 more outperform votes than Vir Biotechnology when rated by MarketBeat users. Likewise, 58.33% of users gave Agiliti an outperform vote while only 48.15% of users gave Vir Biotechnology an outperform vote.
Agiliti has a beta of 1.9, meaning that its share price is 90% more volatile than the S&P 500. Comparatively, Vir Biotechnology has a beta of 0.47, meaning that its share price is 53% less volatile than the S&P 500.
Summary
Agiliti beats Vir Biotechnology on 10 of the 18 factors compared between the two stocks.
Get Agiliti News Delivered to You Automatically
Sign up to receive the latest news and ratings for AGTI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AGTI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
